Fragment-Based Discovery of 6-Arylindazole JAK Inhibitors.

ACS Med Chem Lett

Drug Design, In Vitro Biology, Skin PK and Early Safety, and Preformulation & Early Analytical Development, Global R&D, LEO Pharma A/S , Industriparken 55, DK-2750 Ballerup, Denmark.

Published: June 2016

Janus kinase (JAK) inhibitors are emerging as novel and efficacious drugs for treating psoriasis and other inflammatory skin disorders, but their full potential is hampered by systemic side effects. To overcome this limitation, we set out to discover soft drug JAK inhibitors for topical use. A fragment screen yielded an indazole hit that was elaborated into a potent JAK inhibitor using structure-based design. Growing the fragment by installing a phenol moiety in the 6-position afforded a greatly improved potency. Fine-tuning the substituents on the phenol and sulfonamide moieties afforded a set of compounds with lead-like properties, but they were found to be phototoxic and unstable in the presence of light.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904270PMC
http://dx.doi.org/10.1021/acsmedchemlett.6b00087DOI Listing

Publication Analysis

Top Keywords

jak inhibitors
12
fragment-based discovery
4
discovery 6-arylindazole
4
jak
4
6-arylindazole jak
4
inhibitors janus
4
janus kinase
4
kinase jak
4
inhibitors emerging
4
emerging novel
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!